Shopping Cart 0
Cart Subtotal
USD 0

Heart Pump Device Market: Current Analysis and Forecast (2021-2027)

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4900

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 6860

Details

HEART PUMP DEVICES ARE ALSO KNOWN AS VENTRICULAR ASSIST DEVICES (VAD), IS AN IMPLANTABLE MECHANICAL PUMP WHICH HELPS PUMP BLOOD FROM THE LOWER CHAMBERS OF THE HEART (VENTRICLES) TO THE REST OF THE BODY. THIS DEVICE IS USED IN PEOPLE WITH WEAKENED HEARTS OR HEART FAILURE. HEART PUMPS ARE MOST FREQUENTLY PLACED ON THE LEFT SIDE OF THE HEART AND ARE KNOWN AS LEFT VENTRICULAR ASSIST DEVICE (LVAD). A PERSON CAN HAVE A HEART PUMP IMPLANTED WHILE THEY ARE WAITING FOR A HEART TRANSPLANT OR WHILE ONE'S HEART IS RECOVERING, AS HEART PUMPS CAN SUPPORT THE HEART WHILE THEY ARE RECOVERING. HEART PUMPS CAN ALSO BE IMPLANTED FOR LONG TERM TREATMENTS FOR PATIENTS WITH HEART FAILURE AND ARE NOT ELIGIBLE FOR HEART TRANSPLANTS. HEART PUMP IMPLANTATIONS REQUIRE AN OPEN-HEART SURGERY AND CAN HAVE SERIOUS RISKS. HOWEVER, IN THE CASES OF SEVERE HEART FAILURES, THESE DEVICES CAN BE LIFESAVING.

BASED ON PRODUCT, THE HEART PUMP DEVICES MARKET IS SEGMENTED INTO VENTRICULAR ASSIST DEVICES (VADS), INTRA-AORTIC BALLOON PUMPS (IABPS) AND TOTAL ARTIFICIAL HEART (TAH). THE VENTRICULAR ASSIST DEVICES SEGMENT WAS VALUED AT USD XX MILLION IN 2020 AND IS LIKELY TO REACH USD XX MILLION BY 2027 GROWING AT A CAGR OF XX% FROM 2021-2027. BASED ON TYPE, THE HEART PUMP DEVICES MARKET IS BIFURCATED INTO IMPLANTABLE AND EXTRACORPOREAL HEART PUMP DEVICES. THE IMPLANTABLE HEART PUMP DEVICES ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYSED PERIOD.

BASED ON THERAPY, THE HEART PUMP DEVICES MARKET IS SEGMENTED INTO BRIDGE-TO-TRANSPLANT (BTT), BRIDGE-TO-CANDIDACY (BTC), DESTINATION THERAPY (DT) AND OTHER THERAPIES. BRIDGE-TO-TRANSPLANT (BTT) THERAPY IS EXPECTED TO WITNESS HIGHEST CAGR GROWTH DURING THE FORECAST PERIOD. BRIDGE-TO-TRANSPLANT ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYSED PERIOD.

FOR A BETTER UNDERSTANDING OF THE MARKET ADOPTION OF THE HEART PUMP DEVICE MARKET, THE MARKET IS ANALYSED FOR MAJOR REGIONS INCLUDING NORTH AMERICA (UNITED STATES, CANADA, AND REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UNITED KINGDOM AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA CONSTITUTES A MAJOR MARKET FOR THE HEART PUMP DEVICE MARKET INDUSTRY AND GENERATED REVENUE OF USD XX MILLION IN 2020, OWING TO THE PRESENCE OF WELL-ESTABLISHED PLAYERS IN THE REGION, RISING INVESTMENT BY THE COMPANIES, ETC. SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET ABBOTT LABORATORIES, ABIOMED, MEDTRONIC, TELEFLEX INCORPORATED, SYNCARDIA SYSTEMS, FRESENIUS MEDICAL CARE AG & CO. KGAA, GETINGE, CARDIACASSIST, INC., BERLIN HEART, JARVIK HEART, INC. SEVERAL M&A'S ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.

HEART PUMP DEVICE MARKET WAS VALUED AT USD 1.7 BILLION IN 2020 AND IS PROJECTED TO EXPAND SIGNIFICANTLY WITH A CAGR OF 18.9% FROM 2021-2027F TO USD 6 BILLION IN 2027. THE HEART PUMP DEVICE MARKET IS EXPECTED TO WITNESS A BOOST ON ACCOUNT OF THE GROWING PREVALENCE OF CARDIOVASCULAR DISEASES.
READ MORE

Table Of Content

Scope

1 MARKET INTRODUCTION

1.1. MARKET DEFINITIONS

1.2. OBJECTIVE OF THE STUDY

1.3. LIMITATION

1.4. STAKE HOLDERS

1.5. CURRENCY USED IN REPORT

1.6. SCOPE OF THE HEART PUMP DEVICE MARKET STUDY

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. RESEARCH METHODOLOGY FOR THE HEART PUMP DEVICE MARKET

2.1.1. MAIN OBJECTIVE OF THE HEART PUMP DEVICE MARKET

3 INDUSTRY PERFORMANCE

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 MARKET INSIGHTS BY PRODUCT

6.1. VENTRICULAR ASSIST DEVICES (VADS)

6.1.1. LEFT VENTRICULAR ASSIST DEVICES (LVADS)

6.1.2. RIGHT VENTRICULAR ASSIST DEVICES (RVADS)

6.1.3. BI-VENTRICULAR ASSIST DEVICES (BIVADS)

6.1.4. PERCUTANEOUS VENTRICULAR ASSIST DEVICES (PVADS)

6.2. INTRA-AORTIC BALLOON PUMPS (IABPS)

6.3. TOTAL ARTIFICIAL HEART (TAH)

7 MARKET INSIGHTS BY TYPE

7.1. IMPLANTABLE HEART PUMP DEVICES

7.2. EXTRACORPOREAL HEART PUMP DEVICES

8 MARKET INSIGHTS BY THERAPY

8.1. BRIDGE-TO-TRANSPLANT (BTT)

8.2. BRIDGE-TO-CANDIDANCY (BTC)

8.3. DESTINATION THERAPY (DT)

8.4. OTHER THERAPIES

9 MARKET INSIGHTS BY REGION

9.1. NORTH AMERICA HEART PUMP DEVICE MARKET

9.1.1. UNITED STATES

9.1.2. CANADA

9.1.3. REST OF NORTH AMERICA

9.2. EUROPE HEART PUMP DEVICE MARKET

9.2.1. UNITED KINGDOM

9.2.2. GERMANY

9.2.3. FRANCE

9.2.4. SPAIN

9.2.5. ITALY

9.2.6. REST OF EUROPE

9.3. ASIA-PACIFIC HEART PUMP DEVICE MARKET

9.3.1. CHINA

9.3.2. JAPAN

9.3.3. INDIA

9.3.4. AUSTRALIA

9.3.5. REST OF ASIA-PACIFIC

9.4. REST OF THE WORLD HEART PUMP DEVICE MARKET

10 LEGAL AND REGULATORY FRAMEWORK

11 DEMAND AND SUPPLY SIDE ANALYSIS

11.1. DEMAND SIDE ANALYSIS

11.2. SUPPLY SIDE ANALYSIS

11.2.1. TOP PRODUCT LAUNCHES

11.2.2. TOP BUSINESS PARTNERSHIPS

11.2.3. TOP BUSINESS EXPANSIONS, INVESTMENTS AND DIVESTITURES

11.2.4. TOP MERGER AND ACQUISITIONS

12 VALUE CHAIN ANALYSIS

13 HEART PUMP DEVICE MARKET TRENDS & INSIGHTS

14 HEART PUMP DEVICE MARKET DYNAMICS

14.1. DRIVERS

14.2. CHALLENGES

14.3. IMPACT ANALYSIS

14.4. OPPORTUNITY

15 COMPETITIVE SCENARIO

15.1. HEART PUMP DEVICE MARKET SHARE, BY COMPANY 2020

16 COMPANY PROFILED

16.1. ABBOTT LABORATORIES

16.2. ABIOMED

16.3. MEDTRONIC

16.4. TELEFLEX INCORPORATED

16.5. SYNCARDIA SYSTEMS

16.6. FRESENIUS MEDICAL CARE AG & CO. KGAA

16.7. GETINGE

16.8. CARDIACASSIST, INC.

16.9. BERLIN HEART

16.10. JARVIK HEART, INC.

17 DISCLAIMER

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

ABBOTT LABORATORIES

ABIOMED

MEDTRONIC

TELEFLEX INCORPORATED

SYNCARDIA SYSTEMS

FRESENIUS MEDICAL CARE AG & CO. KGAA

GETINGE

CARDIACASSIST

INC.

BERLIN HEART

JARVIK HEART

INC.

Company Profile

Company Profile Title

HEART PUMP DEVICES ARE ALSO KNOWN AS VENTRICULAR ASSIST DEVICES (VAD), IS AN IMPLANTABLE MECHANICAL PUMP WHICH HELPS PUMP BLOOD FROM THE LOWER CHAMBERS OF THE HEART (VENTRICLES) TO THE REST OF THE BODY. THIS DEVICE IS USED IN PEOPLE WITH WEAKENED HEARTS OR HEART FAILURE. HEART PUMPS ARE MOST FREQUENTLY PLACED ON THE LEFT SIDE OF THE HEART AND ARE KNOWN AS LEFT VENTRICULAR ASSIST DEVICE (LVAD). A PERSON CAN HAVE A HEART PUMP IMPLANTED WHILE THEY ARE WAITING FOR A HEART TRANSPLANT OR WHILE ONE'S HEART IS RECOVERING, AS HEART PUMPS CAN SUPPORT THE HEART WHILE THEY ARE RECOVERING. HEART PUMPS CAN ALSO BE IMPLANTED FOR LONG TERM TREATMENTS FOR PATIENTS WITH HEART FAILURE AND ARE NOT ELIGIBLE FOR HEART TRANSPLANTS. HEART PUMP IMPLANTATIONS REQUIRE AN OPEN-HEART SURGERY AND CAN HAVE SERIOUS RISKS. HOWEVER, IN THE CASES OF SEVERE HEART FAILURES, THESE DEVICES CAN BE LIFESAVING.

BASED ON PRODUCT, THE HEART PUMP DEVICES MARKET IS SEGMENTED INTO VENTRICULAR ASSIST DEVICES (VADS), INTRA-AORTIC BALLOON PUMPS (IABPS) AND TOTAL ARTIFICIAL HEART (TAH). THE VENTRICULAR ASSIST DEVICES SEGMENT WAS VALUED AT USD XX MILLION IN 2020 AND IS LIKELY TO REACH USD XX MILLION BY 2027 GROWING AT A CAGR OF XX% FROM 2021-2027. BASED ON TYPE, THE HEART PUMP DEVICES MARKET IS BIFURCATED INTO IMPLANTABLE AND EXTRACORPOREAL HEART PUMP DEVICES. THE IMPLANTABLE HEART PUMP DEVICES ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYSED PERIOD.

BASED ON THERAPY, THE HEART PUMP DEVICES MARKET IS SEGMENTED INTO BRIDGE-TO-TRANSPLANT (BTT), BRIDGE-TO-CANDIDACY (BTC), DESTINATION THERAPY (DT) AND OTHER THERAPIES. BRIDGE-TO-TRANSPLANT (BTT) THERAPY IS EXPECTED TO WITNESS HIGHEST CAGR GROWTH DURING THE FORECAST PERIOD. BRIDGE-TO-TRANSPLANT ACCOUNTED FOR A MARKET VALUATION OF USD XX MILLION IN 2020 AND IS EXPECTED TO REACH USD XX MILLION BY THE YEAR 2027, AT A CAGR OF XX% OVER THE ANALYSED PERIOD.

FOR A BETTER UNDERSTANDING OF THE MARKET ADOPTION OF THE HEART PUMP DEVICE MARKET, THE MARKET IS ANALYSED FOR MAJOR REGIONS INCLUDING NORTH AMERICA (UNITED STATES, CANADA, AND REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UNITED KINGDOM AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA CONSTITUTES A MAJOR MARKET FOR THE HEART PUMP DEVICE MARKET INDUSTRY AND GENERATED REVENUE OF USD XX MILLION IN 2020, OWING TO THE PRESENCE OF WELL-ESTABLISHED PLAYERS IN THE REGION, RISING INVESTMENT BY THE COMPANIES, ETC. SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET ABBOTT LABORATORIES, ABIOMED, MEDTRONIC, TELEFLEX INCORPORATED, SYNCARDIA SYSTEMS, FRESENIUS MEDICAL CARE AG & CO. KGAA, GETINGE, CARDIACASSIST, INC., BERLIN HEART, JARVIK HEART, INC. SEVERAL M&A'S ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.

HEART PUMP DEVICE MARKET WAS VALUED AT USD 1.7 BILLION IN 2020 AND IS PROJECTED TO EXPAND SIGNIFICANTLY WITH A CAGR OF 18.9% FROM 2021-2027F TO USD 6 BILLION IN 2027. THE HEART PUMP DEVICE MARKET IS EXPECTED TO WITNESS A BOOST ON ACCOUNT OF THE GROWING PREVALENCE OF CARDIOVASCULAR DISEASES.
READ MORE

Scope

1 MARKET INTRODUCTION

1.1. MARKET DEFINITIONS

1.2. OBJECTIVE OF THE STUDY

1.3. LIMITATION

1.4. STAKE HOLDERS

1.5. CURRENCY USED IN REPORT

1.6. SCOPE OF THE HEART PUMP DEVICE MARKET STUDY

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. RESEARCH METHODOLOGY FOR THE HEART PUMP DEVICE MARKET

2.1.1. MAIN OBJECTIVE OF THE HEART PUMP DEVICE MARKET

3 INDUSTRY PERFORMANCE

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 MARKET INSIGHTS BY PRODUCT

6.1. VENTRICULAR ASSIST DEVICES (VADS)

6.1.1. LEFT VENTRICULAR ASSIST DEVICES (LVADS)

6.1.2. RIGHT VENTRICULAR ASSIST DEVICES (RVADS)

6.1.3. BI-VENTRICULAR ASSIST DEVICES (BIVADS)

6.1.4. PERCUTANEOUS VENTRICULAR ASSIST DEVICES (PVADS)

6.2. INTRA-AORTIC BALLOON PUMPS (IABPS)

6.3. TOTAL ARTIFICIAL HEART (TAH)

7 MARKET INSIGHTS BY TYPE

7.1. IMPLANTABLE HEART PUMP DEVICES

7.2. EXTRACORPOREAL HEART PUMP DEVICES

8 MARKET INSIGHTS BY THERAPY

8.1. BRIDGE-TO-TRANSPLANT (BTT)

8.2. BRIDGE-TO-CANDIDANCY (BTC)

8.3. DESTINATION THERAPY (DT)

8.4. OTHER THERAPIES

9 MARKET INSIGHTS BY REGION

9.1. NORTH AMERICA HEART PUMP DEVICE MARKET

9.1.1. UNITED STATES

9.1.2. CANADA

9.1.3. REST OF NORTH AMERICA

9.2. EUROPE HEART PUMP DEVICE MARKET

9.2.1. UNITED KINGDOM

9.2.2. GERMANY

9.2.3. FRANCE

9.2.4. SPAIN

9.2.5. ITALY

9.2.6. REST OF EUROPE

9.3. ASIA-PACIFIC HEART PUMP DEVICE MARKET

9.3.1. CHINA

9.3.2. JAPAN

9.3.3. INDIA

9.3.4. AUSTRALIA

9.3.5. REST OF ASIA-PACIFIC

9.4. REST OF THE WORLD HEART PUMP DEVICE MARKET

10 LEGAL AND REGULATORY FRAMEWORK

11 DEMAND AND SUPPLY SIDE ANALYSIS

11.1. DEMAND SIDE ANALYSIS

11.2. SUPPLY SIDE ANALYSIS

11.2.1. TOP PRODUCT LAUNCHES

11.2.2. TOP BUSINESS PARTNERSHIPS

11.2.3. TOP BUSINESS EXPANSIONS, INVESTMENTS AND DIVESTITURES

11.2.4. TOP MERGER AND ACQUISITIONS

12 VALUE CHAIN ANALYSIS

13 HEART PUMP DEVICE MARKET TRENDS & INSIGHTS

14 HEART PUMP DEVICE MARKET DYNAMICS

14.1. DRIVERS

14.2. CHALLENGES

14.3. IMPACT ANALYSIS

14.4. OPPORTUNITY

15 COMPETITIVE SCENARIO

15.1. HEART PUMP DEVICE MARKET SHARE, BY COMPANY 2020

16 COMPANY PROFILED

16.1. ABBOTT LABORATORIES

16.2. ABIOMED

16.3. MEDTRONIC

16.4. TELEFLEX INCORPORATED

16.5. SYNCARDIA SYSTEMS

16.6. FRESENIUS MEDICAL CARE AG & CO. KGAA

16.7. GETINGE

16.8. CARDIACASSIST, INC.

16.9. BERLIN HEART

16.10. JARVIK HEART, INC.

17 DISCLAIMER

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

ABBOTT LABORATORIES

ABIOMED

MEDTRONIC

TELEFLEX INCORPORATED

SYNCARDIA SYSTEMS

FRESENIUS MEDICAL CARE AG & CO. KGAA

GETINGE

CARDIACASSIST

INC.

BERLIN HEART

JARVIK HEART

INC.